Comments on: IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease

Comments on: IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease https://www.novumpr.nl/2016/05/24/il-23-inhibitor-risankizumab-induces-remission-in-phase-ii-study-in-patients-with-moderate-to-severe-crohns-disease/?utm_source=rss&utm_medium=rss&utm_campaign=il-23-inhibitor-risankizumab-induces-remission-in-phase-ii-study-in-patients-with-moderate-to-severe-crohns-disease NovumPR press releases Tue, 24 May 2016 15:14:24 +0000 hourly 1 https://wordpress.org/?v=6.8.2